Lyudmila Bazhenova, MD, Discusses the Reasoning Behind Testing for EGFR Exon 20 Insertions in NSCLC at 2021 WCLC

Video

CancerNetwork® sat down with Lyudmila Bazhenova, MD, at the 2021 World Conference on Lung Cancer to talk about immunotherapy response in patients with EGFR exon 20 insertion mutations.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Lyudmila Bazhenova, MD, of University of California at San Diego, about methods and objectives of a study that investigated response to immunotherapy in patients with EGFR exon 20 insertion mutant non–small cell lung cancer versus those with wild-type disease.

Transcript:

Patients with EGFR exon 20 insertion [mutations] are the third most prevalent class of EGFR mutant non–small cell lung cancer [and] those patients were excluded from the majority of the clinical trials. With immune checkpoint inhibitors, we really don’t know how those patients perform when given immunotherapy. We also don’t know how many of those patients receive immunotherapy in real life. Therefore, we used our flatiron database spanning the years of 2015 to 2020. The reason why we selected those years was because those were the years where immune checkpoint inhibitors became widely available and used in the community. This [analysis] separated the patients into the EGFR exon 20 insertion [mutant disease] cohort, and a wild-type non–small cell lung cancer cohort, which we defined [with an] EGFR-and ALK-negative test.

Reference

Bazhenova L, Girard N, Minchom A, et al. Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors. Presented at: 2021 World Conference on Lung Cancer; September 8-14, 2021. Virtual. Abstract P08.04.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content